Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan

被引:14
|
作者
Hsu, Ching-Sheng
Liu, Chun-Jen
Lai, Ming-Yang
Chen, Pei-Jer
Kao, Jia-Horng
Chen, Ding-Shinn
机构
[1] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei 100, Taiwan
[2] Buddhist Tzu Chi Gen Hosp, Dept Hepatogastroenterol, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
关键词
hepatitis C virus; viral kinetics; pegylated interferon; interferon; ribavirin;
D O I
10.1159/000105444
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: Early hepatitis C viral ( HCV) kinetics following pegylated interferon-alpha (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-alpha dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters epsilon ( effectiveness at inhibiting viral production) and delta ( loss rate of infected cells) were estimated from viral loads and alanine aminotransferase ( ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The epsilon ranged from 0.4128 to 0.9904 and delta from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [31] Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C
    Seyam, MS
    Freshwater, DA
    O'Donnell, K
    Mutimer, DJ
    [J]. JOURNAL OF VIRAL HEPATITIS, 2005, 12 (05) : 531 - 535
  • [32] Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C
    Yang, Wei-Shun
    Chu, Pei-Lun
    Liu, Chen-Hua
    Chung, Guei-Bin
    Wu, Kwan-Dun
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (01) : 112 - 113
  • [33] Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
    Al-Ali, Jaber
    Siddique, Iqbal
    Varghese, Rosh
    Hasan, Fuad
    [J]. ANNALS OF HEPATOLOGY, 2012, 11 (02) : 186 - 193
  • [34] Effects of Host and virus related factors on Interferon-α plus ribavirin and Pegylated-interferon plus ribavirin treatment outcomes in Chronic Hepatitis C patients
    Akram, Madiha
    Idrees, Muhammad
    Zafar, Shamail
    Hussain, Abrar
    Butt, Sadia
    Afzal, Samia
    Rehman, Irshad-ur
    Liaqat, Ali
    Saleem, Sana
    Ali, Muhammad
    Butt, Azeem
    [J]. VIROLOGY JOURNAL, 2011, 8
  • [35] Kinetics of hepatitis C virus RNA load during pegylated interferon plus ribavirin therapy in treatment-naive Chinese patients
    Chu, Chi-Jen
    Wang, Yuan-Jen
    Hwang, Shinn-Jang
    Lu, Rei-Hwa
    Chang, Full-Young
    Chang, Chiao-Yu
    Yang, Ya-Chun
    Lee, Shou-Dong
    [J]. HEPATO-GASTROENTEROLOGY, 2007, 54 (75) : 866 - 870
  • [36] Pegylated Interferon Alpha-2a and Ribavirin in the Treatment of Children with Chronic Hepatitis C
    Pawlowska, Malgorzata
    Halota, Waldemar
    [J]. GASTROENTEROLOGY, 2009, 136 (05) : A839 - A839
  • [37] Psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic Hepatitis C
    Kaabi, W.
    Youssef, S.
    Litaiem, N.
    El Khalifa, J.
    Jaber, K.
    Dhaoui, M. R.
    Doss, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 73 - 73
  • [38] Soluble TRAIL levels decreased in chronic hepatitis C treatment with pegylated interferon α plus ribavirin: association with viral responses
    Seyman, Derya
    Yalcin, Arzu Didem
    Oztoprak, Nefise
    Genc, Gizem Esra
    Ozen, Nevgun Sepin
    Kizilates, Filiz
    Berk, Hande
    Gumuslu, Saadet
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 7 (12): : 5650 - 5656
  • [39] Chronic hepatitis C: Treatment of pegylated interferon/ribavirin nonresponders
    Shiffman M.L.
    [J]. Current Gastroenterology Reports, 2006, 8 (1) : 46 - 52
  • [40] Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
    Carvalho-Filho, Roberto J.
    Dalgard, Olav
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 1 - 13